Search

Your search keyword '"L. Peyrin"' showing total 374 results

Search Constraints

Start Over You searched for: Author "L. Peyrin" Remove constraint Author: "L. Peyrin" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
374 results on '"L. Peyrin"'

Search Results

1. P664 Analysis of Clinical Trial Screen Failures in IBD: Real World Results from the IOIBD

2. OP35 Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study

3. P520 Thromboembolic and major adverse cardiovascular events among patients in the filgotinib clinical trial programme

4. OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results

5. P696 Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis

6. P379 Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn’s disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies

7. P185 Global perception of normal life by healthcare professionals and IBD patients: mind the gap

8. OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics

9. P375 Izencitinib induction treatment in patients with moderately-to-severely-active Crohn’s Disease: A phase 2 double-blind, randomized, placebo-controlled study

10. P548 Efficacy outcomes of placebo maintenance treatment in patients with moderate to severe Crohn’s disease who responded to placebo induction therapy: Post-hoc analysis of the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Risankizumab Studies

11. P445 Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn’s Disease and Ulcerative Colitis

12. P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

13. P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme

14. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases

16. OP39 Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn’s Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

17. A186 ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION

18. A37 EFFICACY AND SAFETY OF RISANKIZUMAB AS MAINTENANCE THERAPY IN PATIENTS WITH CROHN’S DISEASE: 52 WEEK RESULTS FROM THE PHASE 3 FORTIFY STUDY

19. DOP90 Efficacy of the treat-to-target approach in modifying disease course with ustekinumab in patients with moderate-to-severe Crohn’s Disease: Results from the STARDUST trial

20. OP32 The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo

21. P793 Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis

22. P602 Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

23. P588 Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis

24. P129 Intestinal ultrasound at week 12 predicts long-term endoscopic response to biologics in ulcerative colitis

25. P490 Etrasimod for the treatment of ulcerative colitis: up to 2.5 years of pooled safety data from global clinical trials

26. P631 Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn’s Disease (CD): Results from a large multinational prospective observational study

27. P554 Extended induction response in patients treated with mirikizumab with moderately to severely active ulcerative colitis in the LUCENT trials

28. P619 Inflammatory bowel disease meets fertility: a physicians and patients survey

29. P450 Real life Effectiveness and safety of an induction treatment with tofacitinib in patients with Ulcerative Colitis: First results of the French TOFAST cohort

30. P404 Persistence of subcutaneous infliximab after switching from intravenous in a French national cohort of IBD patients in remission

31. P354 Application of the clinical decision support tool to predict treatment outcomes in Crohn’s Disease patients treated with vedolizumab subcutaneous formulation

32. P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy

33. P577 A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis

34. P777 Deployment of an artificial intelligence tool for precision medicine in ulcerative colitis: Preliminary data from 8 globally distributed clinical sites

35. P151 Assessing comprehensive remission for Ulcerative Colitis in clinical practice: International consensus recommendations

39. ECCO Position on Harmonisation of Crohn's Disease Mucosal Histopathology

40. P330 Ultrasound remission after biologic induction predicts long-term endoscopic remission in Crohn’s disease

41. P734 A single measurement of fecal calprotectin, particularly if combined with hemoglobin and C-reactive protein levels, predicts Crohn’s disease prognosis - a prospective study

42. P385 Risk-benefit assessment of IBD drugs: a physicians and patients survey

43. OP14 Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIO

44. P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study

45. P736 Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trial

46. How to Manage Inflammatory Bowel Disease Patients When They Withdraw Anti-Tumour Necrosis Factor [Anti-TNF] Due to Severe Anti-TNF-Induced Skin Lesions? A Multicentre Cohort Study

47. Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study

48. OMO-2 Filgotinib efficacy in patients with ulcerative colitis by line of therapy: Phase 2b/3 selection results

50. P230 Ultrasonography-based and Magnetic Resonance-based Lémann Index: two sides of the same coin

Catalog

Books, media, physical & digital resources